JP2022522787A5 - - Google Patents
Info
- Publication number
- JP2022522787A5 JP2022522787A5 JP2021551806A JP2021551806A JP2022522787A5 JP 2022522787 A5 JP2022522787 A5 JP 2022522787A5 JP 2021551806 A JP2021551806 A JP 2021551806A JP 2021551806 A JP2021551806 A JP 2021551806A JP 2022522787 A5 JP2022522787 A5 JP 2022522787A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- fusion protein
- linker
- terminus
- sequence shown
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910162060.6 | 2019-03-05 | ||
| CN201910162060 | 2019-03-05 | ||
| CN201910758104 | 2019-08-16 | ||
| CN201910758104.1 | 2019-08-16 | ||
| PCT/CN2020/077750 WO2020177712A1 (en) | 2019-03-05 | 2020-03-04 | A polypeptide molecule and application thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022522787A JP2022522787A (ja) | 2022-04-20 |
| JP2022522787A5 true JP2022522787A5 (https=) | 2023-02-09 |
| JP7664168B2 JP7664168B2 (ja) | 2025-04-17 |
Family
ID=72338401
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021551806A Active JP7664168B2 (ja) | 2019-03-05 | 2020-03-04 | ポリペプチド分子及びその適用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12590132B2 (https=) |
| EP (1) | EP3935075A4 (https=) |
| JP (1) | JP7664168B2 (https=) |
| KR (1) | KR20210137093A (https=) |
| CN (2) | CN118388627A (https=) |
| AU (2) | AU2020230668B2 (https=) |
| CA (1) | CA3123325A1 (https=) |
| WO (1) | WO2020177712A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112661858A (zh) * | 2020-12-03 | 2021-04-16 | 安徽安科生物工程（集团）股份有限公司 | 重组人生长激素Fc融合蛋白和用途及其工程细胞株 |
| US20240165202A1 (en) * | 2021-03-19 | 2024-05-23 | Sunshine Lake Pharma Co., Ltd. | Uses of fgf21 polypeptides and fusion polypeptides thereof |
| CN115991793A (zh) * | 2023-01-16 | 2023-04-21 | 上海民为生物技术有限公司 | 具有多重活性的融合蛋白及其应用 |
| EP4732829A1 (en) * | 2023-06-20 | 2026-04-29 | Sunshine Lake Pharma Co., Ltd. | Glp-1-fc-fgf21 double-target fusion protein composition, and injection and use thereof |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6110893A (en) * | 1995-06-05 | 2000-08-29 | Human Genome Sciences, Inc. | Fibroblast growth factor 11 |
| DK1641823T3 (da) * | 2003-06-12 | 2011-12-12 | Lilly Co Eli | GLP-1-analog fusionsproteiner |
| EP2194064A1 (en) | 2004-05-13 | 2010-06-09 | Eli Lilly & Company | FGF-21 fusion proteins |
| US7622445B2 (en) | 2004-09-02 | 2009-11-24 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
| KR100854198B1 (ko) | 2004-09-02 | 2008-08-26 | 일라이 릴리 앤드 캄파니 | 섬유아세포 성장 인자 21의 뮤테인 |
| US7655627B2 (en) | 2004-12-14 | 2010-02-02 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
| US20110034373A1 (en) | 2007-08-03 | 2011-02-10 | Eli Lilly And Company | Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity |
| US8034770B2 (en) | 2008-06-04 | 2011-10-11 | Amgen Inc. | FGF21 polypeptides comprising two or more mutations |
| CA2739615C (en) | 2008-10-10 | 2017-12-05 | Amgen Inc. | Fgf21 mutants comprising polyethylene glycol and uses thereof |
| ES2610356T3 (es) * | 2009-02-03 | 2017-04-27 | Amunix Operating Inc. | Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos |
| WO2010129600A2 (en) | 2009-05-05 | 2010-11-11 | Amgen Inc. | Fgf21 mutants and uses thereof |
| WO2010129503A1 (en) * | 2009-05-05 | 2010-11-11 | Amgen Inc. | Fgf21 mutants and uses thereof |
| CN101993496B (zh) | 2009-08-20 | 2013-06-05 | 重庆富进生物医药有限公司 | 双重调节血糖血脂融合蛋白及其制法和用途 |
| MX2014002260A (es) | 2011-08-31 | 2014-08-18 | Amgen Inc | Factor de crecimiento de fibroblasto 21 para usar en el tratamiento de diabetes tipo 1. |
| UY34347A (es) * | 2011-09-26 | 2013-04-30 | Novartis Ag | Proteínas de función dual para tratar trastornos metabólicos |
| AR087973A1 (es) * | 2011-10-04 | 2014-04-30 | Lilly Co Eli | Variantes del factor 21 del crecimiento de fibroblastos |
| MA37506B1 (fr) | 2012-05-15 | 2017-03-31 | Lilly Co Eli | Utilisations thérapeutiques de protéines de facteur de croissance des fibroblastes 21 |
| TWI513705B (zh) | 2012-06-11 | 2015-12-21 | Lilly Co Eli | 纖維母細胞生長因子２１蛋白質 |
| CA2871656A1 (en) | 2012-06-11 | 2013-12-19 | Eli Lilly And Company | Fibroblast growth factor 21 variants |
| TW201420606A (zh) | 2012-08-22 | 2014-06-01 | Lilly Co Eli | 同源二聚體蛋白 |
| JP6822839B2 (ja) * | 2013-09-13 | 2021-01-27 | ザ・スクリップス・リサーチ・インスティテュート | 修飾された治療剤、及びその組成物 |
| WO2015061351A1 (en) * | 2013-10-21 | 2015-04-30 | Salk Institute For Biological Studies | Chimeric fibroblast growth factor (fgf) 2/fgf1 peptides and methods of use |
| WO2016048999A2 (en) * | 2014-09-23 | 2016-03-31 | Salk Institute For Biological Studies | Fgf21 truncations and mutants and uses thereof |
| KR20160088656A (ko) * | 2015-01-16 | 2016-07-26 | 주식회사유한양행 | 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물 |
| CN106397569B (zh) * | 2015-08-01 | 2020-09-01 | 深圳红石科创生物科技发展有限公司 | 一种治疗代谢疾病的突变细胞因子融合蛋白 |
| US20180280474A1 (en) | 2015-10-01 | 2018-10-04 | Amgen Inc. | Treatment of bile acid disorders |
| KR102670157B1 (ko) | 2015-10-28 | 2024-05-29 | 주식회사유한양행 | 이중 작용 단백질 및 이를 포함하는 약학적 조성물 |
| KR102668200B1 (ko) * | 2015-10-28 | 2024-05-23 | 주식회사유한양행 | 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물 |
| KR20170080526A (ko) * | 2015-12-31 | 2017-07-10 | 한미약품 주식회사 | Fgf21 아날로그, fgf21 결합체, 및 이의 용도 |
| EP3442997A2 (en) | 2016-04-15 | 2019-02-20 | Indiana University Research & Technology Corporation | Fgf21 c-terminal peptide optimization |
| CN106317226B (zh) * | 2016-08-19 | 2017-09-05 | 安源医药科技（上海）有限公司 | 用于构建融合蛋白的连接肽 |
| MX2019005380A (es) | 2016-11-10 | 2019-08-12 | Yuhan Corp | Composicion farmaceutica que comprende proteinas de fusion para prevenir o tratar la hepatitis, la fibrosis hepatica y la cirrosis hepatica. |
| CN108440668A (zh) * | 2017-02-16 | 2018-08-24 | 瑞阳(苏州)生物科技有限公司 | Fgf21与igf-1的融合蛋白及其应用 |
| WO2018166461A1 (en) * | 2017-03-14 | 2018-09-20 | Sunshine Lake Pharma Co., Ltd. | Dual-target fusion proteins comprising the fc portion of an immunoglobulin |
| CN108623691B (zh) * | 2017-03-17 | 2020-05-15 | 北京比洋生物技术有限公司 | IgG样长效免疫融合蛋白及其应用 |
| AU2019218147B2 (en) * | 2018-02-08 | 2023-06-08 | Sunshine Lake Pharma Co., Ltd. | FGF21 variant, fusion protein and application thereof |
-
2020
- 2020-03-04 EP EP20767280.9A patent/EP3935075A4/en active Pending
- 2020-03-04 AU AU2020230668A patent/AU2020230668B2/en active Active
- 2020-03-04 US US17/418,624 patent/US12590132B2/en active Active
- 2020-03-04 CA CA3123325A patent/CA3123325A1/en active Pending
- 2020-03-04 CN CN202410496064.9A patent/CN118388627A/zh active Pending
- 2020-03-04 KR KR1020217031717A patent/KR20210137093A/ko not_active Ceased
- 2020-03-04 CN CN202010143690.1A patent/CN111662373B/zh active Active
- 2020-03-04 WO PCT/CN2020/077750 patent/WO2020177712A1/en not_active Ceased
- 2020-03-04 JP JP2021551806A patent/JP7664168B2/ja active Active
-
2025
- 2025-08-28 AU AU2025223814A patent/AU2025223814A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022522787A5 (https=) | ||
| FI3368555T3 (fi) | Kaksitoimisia proteiineja ja niitä sisältävä farmaseuttinen koostumus | |
| JP2008500373A5 (https=) | ||
| JPH07508025A (ja) | インスリン様増殖因子（ｉｇｆ−１）類似体 | |
| US20180028676A1 (en) | Methods and compositions for treatment of forbes-cori disease | |
| JP2014524908A5 (https=) | ||
| JP2015522576A (ja) | 血小板由来成長因子に結合する設計アンキリンリピートタンパク質 | |
| JP2016183180A (ja) | 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド | |
| US20070244041A1 (en) | Peptide Yy Analogues | |
| JP2021512159A5 (https=) | ||
| JP2023040169A5 (https=) | ||
| TW201425339A (zh) | 用於治療心臟衰竭之合成線狀愛帕琳（ａｐｅｌｉｎ）模擬物 | |
| JP2024532503A5 (https=) | ||
| JP2026035742A5 (https=) | ||
| WO2023110983A1 (en) | Designed repeat domains with dual binding specificity and their use | |
| CN116615251A (zh) | 包含glp1肽模拟物的抗体-药物缀合物及其用途 | |
| JP2026501203A (ja) | アクチビン受容体ｉｉｂ型バリアント及びその使用 | |
| EP1590458A2 (en) | Bradykinin b2 receptor antagonist peptide from amphibian skin | |
| AU2009265327A1 (en) | Insulin fusion polypeptides | |
| MX2012005912A (es) | Conjugado de polipeptido. | |
| WO2025096921A1 (en) | Peptide acids as a glp1r agonist and antibody-drug conjugates thereof | |
| Mezo et al. | Structure–activity relationships of a peptide inhibitor of the human FcRn: human IgG interaction | |
| JP2022523047A5 (https=) | ||
| JP2025516139A5 (https=) | ||
| JP2024546916A5 (https=) |